Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with hemophilia A and inhibitors to factor VIII South San Francisco, CA December 21, 2016 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that